Dupilumab for treating Chronic obstructive pulmonary disease (COPD)

Dupilumab is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) in adults aged 40 years and older. COPD is the name for a group of lung conditions that cause breathing difficulties. It is a disease that causes obstructed airflow from the lungs. It is typically caused by long-term exposure to irritating gasses or matter, most often from cigarette smoke. Symptoms include difficulty breathing, coughing, mucus production and wheezing. People with COPD are at increased risk of developing heart disease, lung cancer and a variety of other conditions. There is currently an unmet need for appropriate treatment options for COPD.